Sentinel lymph node localization in early breast cancer

Seza A. Gulec, Frederick L Moffat, Robert G. Carroll, Aldo N Serafini, George N Sfakianakis, Lisa Alien, Jodeen Boggs

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Methods: Thirty-two patients with clinical node-negative breast cancer underwent sentinel node localization study as part of a National Cancer Institute-sponsored multicenter trial. Anatomical and histopathologic characteristics of sentinel lymph node (SLN) and a kinetic analysis of nodal uptake were studied. Patients were injected with 1 mCi/4 ml unfiltered 99mTc-sulfur colloid in four divided doses around the palpable lesion or immediately adjacent to the excision cavity if prior biopsy was performed. SLN biopsy was performed 1.5-6 hr (mean = 3 hr) postinjection. Intraoperative localization was performed using a gamma probe. All patients underwent complete axillary dissection. Results: SLN was identified in 30 of 32 (94%) patients. There were no false-negative SLN biopsies. Conclusion: This study supports the clinical validity of SLN biopsy in breast cancer and confirms that, unlike the blue dye technique, the learning curve with unfiltered 99mTc-sulfur colloid and the gamma detection probe is short, and SLN localization is achievable in over 90% of cases by surgeons with modest experience. The use of unfiltered 99mTc-sulfur colloid (larger particle size) with larger injected volume permits effective localization of SLNs.

Original languageEnglish
Pages (from-to)1388-1393
Number of pages6
JournalJournal of Nuclear Medicine
Volume39
Issue number8 SUPPL.
StatePublished - Aug 24 1998

Fingerprint

Sentinel Lymph Node Biopsy
Colloids
Sulfur
Breast Neoplasms
Learning Curve
National Cancer Institute (U.S.)
Particle Size
Multicenter Studies
Dissection
Coloring Agents
Biopsy
Sentinel Lymph Node

Keywords

  • Breast cancer
  • Intraoperative gamma probe
  • Sentinel node
  • Sulfur colloid

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Gulec, S. A., Moffat, F. L., Carroll, R. G., Serafini, A. N., Sfakianakis, G. N., Alien, L., & Boggs, J. (1998). Sentinel lymph node localization in early breast cancer. Journal of Nuclear Medicine, 39(8 SUPPL.), 1388-1393.

Sentinel lymph node localization in early breast cancer. / Gulec, Seza A.; Moffat, Frederick L; Carroll, Robert G.; Serafini, Aldo N; Sfakianakis, George N; Alien, Lisa; Boggs, Jodeen.

In: Journal of Nuclear Medicine, Vol. 39, No. 8 SUPPL., 24.08.1998, p. 1388-1393.

Research output: Contribution to journalArticle

Gulec, SA, Moffat, FL, Carroll, RG, Serafini, AN, Sfakianakis, GN, Alien, L & Boggs, J 1998, 'Sentinel lymph node localization in early breast cancer', Journal of Nuclear Medicine, vol. 39, no. 8 SUPPL., pp. 1388-1393.
Gulec SA, Moffat FL, Carroll RG, Serafini AN, Sfakianakis GN, Alien L et al. Sentinel lymph node localization in early breast cancer. Journal of Nuclear Medicine. 1998 Aug 24;39(8 SUPPL.):1388-1393.
Gulec, Seza A. ; Moffat, Frederick L ; Carroll, Robert G. ; Serafini, Aldo N ; Sfakianakis, George N ; Alien, Lisa ; Boggs, Jodeen. / Sentinel lymph node localization in early breast cancer. In: Journal of Nuclear Medicine. 1998 ; Vol. 39, No. 8 SUPPL. pp. 1388-1393.
@article{a423b38fd3784c79b96c6da126c5da9a,
title = "Sentinel lymph node localization in early breast cancer",
abstract = "Methods: Thirty-two patients with clinical node-negative breast cancer underwent sentinel node localization study as part of a National Cancer Institute-sponsored multicenter trial. Anatomical and histopathologic characteristics of sentinel lymph node (SLN) and a kinetic analysis of nodal uptake were studied. Patients were injected with 1 mCi/4 ml unfiltered 99mTc-sulfur colloid in four divided doses around the palpable lesion or immediately adjacent to the excision cavity if prior biopsy was performed. SLN biopsy was performed 1.5-6 hr (mean = 3 hr) postinjection. Intraoperative localization was performed using a gamma probe. All patients underwent complete axillary dissection. Results: SLN was identified in 30 of 32 (94{\%}) patients. There were no false-negative SLN biopsies. Conclusion: This study supports the clinical validity of SLN biopsy in breast cancer and confirms that, unlike the blue dye technique, the learning curve with unfiltered 99mTc-sulfur colloid and the gamma detection probe is short, and SLN localization is achievable in over 90{\%} of cases by surgeons with modest experience. The use of unfiltered 99mTc-sulfur colloid (larger particle size) with larger injected volume permits effective localization of SLNs.",
keywords = "Breast cancer, Intraoperative gamma probe, Sentinel node, Sulfur colloid",
author = "Gulec, {Seza A.} and Moffat, {Frederick L} and Carroll, {Robert G.} and Serafini, {Aldo N} and Sfakianakis, {George N} and Lisa Alien and Jodeen Boggs",
year = "1998",
month = "8",
day = "24",
language = "English",
volume = "39",
pages = "1388--1393",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "8 SUPPL.",

}

TY - JOUR

T1 - Sentinel lymph node localization in early breast cancer

AU - Gulec, Seza A.

AU - Moffat, Frederick L

AU - Carroll, Robert G.

AU - Serafini, Aldo N

AU - Sfakianakis, George N

AU - Alien, Lisa

AU - Boggs, Jodeen

PY - 1998/8/24

Y1 - 1998/8/24

N2 - Methods: Thirty-two patients with clinical node-negative breast cancer underwent sentinel node localization study as part of a National Cancer Institute-sponsored multicenter trial. Anatomical and histopathologic characteristics of sentinel lymph node (SLN) and a kinetic analysis of nodal uptake were studied. Patients were injected with 1 mCi/4 ml unfiltered 99mTc-sulfur colloid in four divided doses around the palpable lesion or immediately adjacent to the excision cavity if prior biopsy was performed. SLN biopsy was performed 1.5-6 hr (mean = 3 hr) postinjection. Intraoperative localization was performed using a gamma probe. All patients underwent complete axillary dissection. Results: SLN was identified in 30 of 32 (94%) patients. There were no false-negative SLN biopsies. Conclusion: This study supports the clinical validity of SLN biopsy in breast cancer and confirms that, unlike the blue dye technique, the learning curve with unfiltered 99mTc-sulfur colloid and the gamma detection probe is short, and SLN localization is achievable in over 90% of cases by surgeons with modest experience. The use of unfiltered 99mTc-sulfur colloid (larger particle size) with larger injected volume permits effective localization of SLNs.

AB - Methods: Thirty-two patients with clinical node-negative breast cancer underwent sentinel node localization study as part of a National Cancer Institute-sponsored multicenter trial. Anatomical and histopathologic characteristics of sentinel lymph node (SLN) and a kinetic analysis of nodal uptake were studied. Patients were injected with 1 mCi/4 ml unfiltered 99mTc-sulfur colloid in four divided doses around the palpable lesion or immediately adjacent to the excision cavity if prior biopsy was performed. SLN biopsy was performed 1.5-6 hr (mean = 3 hr) postinjection. Intraoperative localization was performed using a gamma probe. All patients underwent complete axillary dissection. Results: SLN was identified in 30 of 32 (94%) patients. There were no false-negative SLN biopsies. Conclusion: This study supports the clinical validity of SLN biopsy in breast cancer and confirms that, unlike the blue dye technique, the learning curve with unfiltered 99mTc-sulfur colloid and the gamma detection probe is short, and SLN localization is achievable in over 90% of cases by surgeons with modest experience. The use of unfiltered 99mTc-sulfur colloid (larger particle size) with larger injected volume permits effective localization of SLNs.

KW - Breast cancer

KW - Intraoperative gamma probe

KW - Sentinel node

KW - Sulfur colloid

UR - http://www.scopus.com/inward/record.url?scp=0031829229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031829229&partnerID=8YFLogxK

M3 - Article

C2 - 9708514

AN - SCOPUS:0031829229

VL - 39

SP - 1388

EP - 1393

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 8 SUPPL.

ER -